Wenjun Li1, Chunming Xie1,2, Zhilin Wu1, Jennifer Jones3, Piero Antuono3, Thomas McRae4, Shi-Jiang Li1,5
1Biophysics, Medical College of Wisconsin, Milwaukee, WI, USA; 2Neurology, School of Clinical Medicine, Southeaset University, Nanjing, Jiang Su, China; 3Neurology, Medical College of Wisconsin, Milwaukee, WI, USA; 4Pfizer, Inc.; 5Psychiatry, Medical College of Wisconsin, Milwaukee, WI, USA
Cholinergic inhibitor (Aricept) has proven to be successful in improving the cognitive function of adults with Alzheimers disease (AD). We hypothesize that since the cortical and hippocampal areas receive major cholinergic input from the basal forebrain nuclei, treatment with Aricept can improve the cholinergic activity of AD; it will improve connectivity of the hippocampus network.